BioSpace News Archive

Phase 1/2 pheNIX Trial Would Represent First PKU Gene Therapy to Enter the Clinic

Motif Bio plc, a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced that four iclaprim abstracts have been accepted for presentation at the upcoming 28th European Congress of Clinical Microbiology and Infectious Diseases to be held in Amsterdam, The Netherlands, April 13-16, 2019.

Single intravenous dose phase 1 trial showed that AIC649 was safe and well tolerated in all dose groups

Cytovant licenses East Asian rights for a research-stage T cell receptor (TCR) against tumor antigen NY-ESO-1 as well as rights for Medigene’s dendritic cell (DC) vaccine for the treatment of patients across East Asia

The Pennsylvania-based company disagrees with the FDA’s analysis of its clinical data and will seek to work with the agency for approval.

“Men with breast cancer have limited treatment options, making access to medicines such as Ibrance critically important,” stated Bret Miller, founder of the Male Breast Cancer Coalition.

The FDA calendar has only one PDUFA data scheduled for the next couple weeks. On Thursday, April 11, the U.S. Food and Drug Administration (FDA) and Merck & Co. have a target action date for their supplemental Biologics License Application (sBLA) for Keytruda

A review of top officials at Memorial Sloan Kettering Cancer Center found that there were repeated violations on financial conflicts of interest. The review was conducted by law firm Debevoise & Plimpton and jointly reported by The New York Times and ProPublica.

Independent Public Clinical Hospital No. 4 in Lublin is the first hospital outside of Germany to offer NanoTherm Therapy for the treatment of brain tumor patients

The latest job cuts at Merrimack come about five months after the company culled 60 percent of its staff.